RedHill Biopharma (RDHL) Total Liabilities (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Total Liabilities data on file, last reported at $21.1 million in Q4 2025.

• Total Liabilities for Q4 2025 came in at $21.1 million, down 7.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.1 million (down 7.26% YoY), and the FY2025 annual result was $21.1 million, down 7.26% from the prior year.
• Total Liabilities fell to $21.1 million in Q4 2025 per RDHL's latest filing, from $22.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $203.2 million in Q3 2022 and troughed at $741000.0 in Q4 2023.
• A 5-year average of $94.9 million and a median of $56.8 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities sank 98.48% in 2022, then jumped 2966.94% in 2024.
• A 5-year view of Total Liabilities shows it stood at $172.3 million in 2021, then slumped by 98.48% to $2.6 million in 2022, then plunged by 71.75% to $741000.0 in 2023, then jumped by 2966.94% to $22.7 million in 2024, then decreased by 7.26% to $21.1 million in 2025.
• Business Quant data shows RDHL's Total Liabilities at $21.1 million in Q4 2025, $22.8 million in Q2 2025, and $22.7 million in Q4 2024.